A Phase 1/2 interventional study of INT-210 Capsule and INT-210 Capsule in Ulcerative Colitis (UC), sponsored by Innatus Therapeutics (Shanghai) Co., Ltd.. Recruiting at 15 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-09.
Sponsored by Innatus Therapeutics (Shanghai) Co., Ltd. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 184 studies in Colitis, Ulcerative with a site in China — 73 open to participants now, 96 under way, 25 of them phase 3. Colitis, Ulcerative · China.
Among the 184 studies in Colitis, Ulcerative with a site in China, this one is the 125th largest by planned enrollment of the 136 interventional ones that give a count, is one of 28 that started in 2026, is one of 7 in phase 1/2, reaches primary completion later than 70 of the 95 other live ones, and was the 172nd registered.
1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.
Browse Colitis, Ulcerative studies →73 of the 184 studies in Colitis, Ulcerative with a site in China are open now. Recruiting first, the newest first:
Accro Bioscience (Suzhou) Limited · Sites in China
Ages 18–75
Nanjing Immunophage Biotech Co., Ltd · Sites in China
Ages 18–70
Second Affiliated Hospital of Wenzhou Medical University · Sites in China
Ages 18+
The Second Hospital of Nanjing Medical University · Sites in China
Ages 18–75
Janssen Research & Development, LLC · Sites in China, United States, Argentina and 30 more countries
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
184 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 47 · Phase 3 37 · Phase 4 11
First in 2009; this study’s year is marked. 28 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 70 across 1,239 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 121 across the 136 interventional studies, 176 across the 48 observational. Of the 58 that completed or were terminated, 15 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 184 have an industry lead sponsor. The 10 most frequent:
Innatus Therapeutics (Shanghai) Co., Ltd. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Innatus Therapeutics (Shanghai) Co., Ltd. has 1 study filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
27 of the studies in Colitis, Ulcerative with a site in China that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT06260163Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | 2027-02-10 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
| NCT03221036Phase 3TakedaEfficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis | 2027-09-24 |
Add all 27 to your calendar (.ics) → With an account.
Among the 184 studies in Colitis, Ulcerative with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Multicenter, Randomized, Open-label Clinical Study to Evaluate the Safety and Efficacy of INT-210 Capsules in Participants with Active Ulcerative Colitis.
The study aims to evaluate the safety, efficacy, pharmacokinetic (PK) characteristics, pharmacodynamic (PD) characteristics of INT-210 in participants with active ulcerative colitis (UC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If participants are currently using the following drugs to treat UC, they must also meet the following requirements:
Exclusion Criteria:
Evidence of unresected adenoma or dysplasia in the colon, including lowgrade or high-grade atypical hyperplasia, and unclassified atypical hyperplasia; presence of high-risk progressive adenoma, defined as:
① Adenoma diameter ≥10 mm; or ② Villous adenoma or mixed adenoma with villous structure exceeding 25%; or ③ Accompanied by high-grade intraepithelial neoplasia.
Participants receiving the following drug therapies:
Use of non-steroidal anti-inflammatory drugs (excluding stable use of
≤100 mg/day aspirin for prevention of cardiovascular and cerebrovascular diseases and temporary use of ≤2000 mg/day acetaminophen for no more than three days for infectious pyrexia or mild to moderate pain), intestinal probiotics (including fecal transplant), fish oil, JAK inhibitors, immunoadsorption therapy, Chinese herbal medicines, or compound preparations containing Chinese herbal medicines within 2 weeks prior to randomization;
Any of the following abnormalities in screening laboratory tests:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: INT-210 Capsule
Drug: INT-210 Capsule
All participants will receive oral treatment with INT-210 capsule 200 mg twice daily, starting from Day 1 (D1) of the treatment period (12 weeks).
All participants will receive oral treatment with INT-210 capsule 400 mg twice daily, starting from Day 1 (D1) of the treatment period (12 weeks)
The incidence of treatment-emergent adverse events
Number of participants with treatment-related adverse events as assessed. The incidence of treatment-emergent adverse events will be measured using a combination of data collection methods, including tracking adverse events and assessing their onset or worsening relative to the initiation of treatment. The most recent version of the Medical Dictionary for Regulatory Activities (MedDRA) preferred terms will be used to classify adverse events, including their relationship to the treatment and maximum severity.
Time frame: From enrollment through the safety follow-up visit on Day 92
Treatment-emergent potentially clinically- significant abnormalities in safety laboratory parameters-hematology
Time frame: From enrollment through the safety follow-up visit on Day 92
Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: blood chemistry
Time frame: From enrollment through the safety follow-up visit on Day 92
Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: serum ferritin
Time frame: From enrollment through the safety follow-up visit on Day 92
Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: coagulation
Time frame: From enrollment through the safety follow-up visit on Day 92
Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: urinalysis
Time frame: From enrollment through the safety follow-up visit on Day 92
Treatment-emergent potentially clinically significant abnormalities in electrocardiogram values: QTcF (milliseconds)
A standard 12-lead ECG will be used to collect ventricular rate, PR interval, QRS duration, QT interval, QTcF interval (Fridericia's correction), and ECG result description; the participant must rest for at least 5 minutes before the test. The investigator (or designated personnel) will clinically evaluate each 12-lead ECG.
Time frame: From enrollment through the safety follow-up visit on 92
Treatment-emergent potentially clinically significant abnormalities in vital signs: heart rate (beats per minute)
Time frame: From enrollment through the safety follow-up visit on Day 92
Treatment-emergent potentially clinically significant abnormalities in vital signs: blood pressure (mmHg)
Time frame: From enrollment through the safety follow-up visit on Day 92
Treatment-emergent potentially clinically significant abnormalities in vital signs: respiration rate (BPM)
Time frame: From enrollment through the safety follow-up visit on Day 92
Treatment-emergent potentially clinically significant abnormalities in vital signs: temperature (℃)
Time frame: From enrollment through the safety follow-up visit on Day 92
Pharmacokinetics parameter: Cmax of INT-210
Maximum observed plasma concentration
Time frame: From Day 1 to Day 85
Pharmacokinetics parameter: Cmax_ss of INT-210
Peak Steady-state Concentration
Time frame: rom Day 1 to Day 85
Pharmacokinetics parameter: Cmin_ss of INT-210
Trough Steady-state Concentration
Time frame: From Day 1 to Day 85
Pharmacokinetics parameter: Cave_ss of INT-210
Average Steady-state Blood Drug Level
Time frame: From Day 1 to Day 85
Pharmacokinetics parameter: AUC0-inf of INT-210
Area under the curve from time 0 extrapolated to infinite time (AUCinf) of INT-210
Time frame: From Day1 to Day 85
Pharmacokinetics parameter: AUC0-t of INT-210
Area Under the Plasma Drug concentration-time Curve from Time 0 to the Last Measurement
Time frame: From Day 1 to Day 85
Pharmacokinetics parameter: AUCss
Area Under the Steady-state Blood drug Concentration-time Curve
Time frame: From Day 1 to Day 85
Pharmacokinetics parameter: Tmax of INT-210
Time of maximum observed concentration (Tmax)
Time frame: From Day 1 to Day 85
Pharmacokinetics parameter: T1/2 of INT-210
Half-life (T1/2) (hours)
Time frame: From Day 1 to Day 85
Pharmacokinetics parameter: CL/F of INT-210
Apparent Plasma Clearance
Time frame: From Day 1 to Day 85
Pharmacokinetics parameter: Kel of INT-210
Elimination Rate Constant
Time frame: From Day 1 to Day 85
Pharmacokinetics parameter: MRT of INT-210
Mean Residence Time
Time frame: From Day1 to Day 85
Pharmacokinetics parameter: Vz/F of INT-210
Apparent Volume of Distribution
Time frame: From Day 1 to Day 85
Pharmacokinetics parameter: DF of INT-210
Degree of Fluctuation
Time frame: From Day 1 to Day 85
Pharmacokinetics parameter: RAAUC0-t of INT-210
Accumulation Ratio Calculated Based on AUC
Time frame: From Day 1 to Day 85
Pharmacokinetics parameter: RACmax of INT-210
Accumulation Ratio Calculated Based on Cmax
Time frame: From Day 1 to Day 85
Clinical Remission Rate
The modified Mayo score (MMS) is uesd for assessing the disease activity of UC, including the Rectal Bleeding Subscore (RBS), Stool Frequency Subscore (SFS), and Endoscopy Subscore (ES). The score for each sub-item ranges from 0-3, and the total MMS score ranges from 0-9. A higher score indicates more severe disease, and the total score is a comprehensive assessment of active UC. The percentage of participants who, after taking INT-210, achieve a modified Mayo score ≤2, with an ES ≤1 (excluding "friability" assessment), RBS=0, SFS≤1, and with no increase from baseline in the above 3 subscores.
Time frame: From Day 0 to Day 85
Clinical Response Rate
The percentage of participants who, after taking INT-210, have a decrease in their modified Mayo score of ≥2 points and ≥30% from baseline, and a decrease in RBS of ≥1 point or an absolute RBS of ≤1
Time frame: From Day 0 to Day 85
Endoscopic Remission Rate
The percentage of participants who, after taking INT-210, have an ES ≤1 (excluding "friability" assessment)
Time frame: From Day 0 to Day 85
Histological Improvement Rate
The percentage of participants who, after taking INT-210, achieve a Geboes Index Score (GS) ≤3.1, and an ES=0/1 in the MMS (excluding "friability" assessment).
Time frame: From Day 0 to Day 85
Mucosal Healing Rate
The percentage of participants who, after taking INT-210, have a GS ≤2B.1
Time frame: From Day 0 to Day 85
Symptomatic Remission Rate
The percentage of participants who, after taking INT-210, have an SFS = 0/1 and an RBS = 0.
Time frame: From Day 0 to Day 85
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Jun 2028, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Innatus Therapeutics (Shanghai) Co., Ltd.